Design and Synthesis of C-19 Isosteviol Derivatives as Potent and Highly Selective Antiproliferative Agents.
Clicks: 765
ID: 81120
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
74.2
/100
765 views
465 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #10 of 729 articles by views in molecules
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 729 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Six series of novel isosteviol derivatives; modified in the C-19 position; were synthesized; and their antiproliferative activity was evaluated against three human cancer cell lines (HCT-116; BEL-7402; HepG2) and the human L02 normal cell line in vitro. Most of the derivatives tested here exhibited improved antiproliferative activity with high selectivity when compared with the parent compound isosteviol and the positive control drug 5-fluorouracil. Among these derivatives; compound exhibited the most potent antiproliferative activity and commendable selectivity between cancer and normal cells. In addition; compound inhibited the colony formation of HCT-116 cells in a concentration-dependent manner. Further studies revealed that compound arrested the HCT-116 cell cycle in the S phase; and western blot analysis demonstrated the mechanism may be correlated with a change in the expression of cyclin A; cyclin B1; and cyclin E1. Furthermore; the results of a docking study that involved placing compound into the CDK2/cyclin A binding site revealed that its mode of action was possibly as a CDK2/cyclin A inhibitor.
| Reference Key |
luan2018designmolecules
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Luan, Tian;Cao, Li-Hua;Deng, Hao;Shen, Qing-Kun;Tian, Yu-Shun;Quan, Zhe-Shan; |
| Journal | molecules |
| Year | 2018 |
| DOI |
E121
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.